HighTide Therapeutics Management
Management criteria checks 1/4
HighTide Therapeutics' CEO is Liping Liu, appointed in Feb 2018, has a tenure of 6.83 years. total yearly compensation is CN¥14.66M, comprised of 24.1% salary and 75.9% bonuses, including company stock and options. directly owns 0.96% of the company’s shares, worth HK$5.90M. The average tenure of the management team and the board of directors is 2.9 years and 1.8 years respectively.
Key information
Liping Liu
Chief executive officer
CN¥14.7m
Total compensation
| CEO salary percentage | 24.1% |
| CEO tenure | 6.8yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2.9yrs |
| Board average tenure | 1.8yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥601m |
| Mar 31 2024 | n/a | n/a | -CN¥770m |
| Dec 31 2023 | CN¥15m | CN¥4m | -CN¥939m |
| Sep 30 2023 | n/a | n/a | -CN¥803m |
| Jun 30 2023 | n/a | n/a | -CN¥666m |
| Mar 31 2023 | n/a | n/a | -CN¥428m |
| Dec 31 2022 | CN¥7m | CN¥4m | -CN¥190m |
| Dec 31 2021 | CN¥7m | CN¥3m | -CN¥221m |
Compensation vs Market: Liping's total compensation ($USD2.01M) is above average for companies of similar size in the Hong Kong market ($USD231.18K).
Compensation vs Earnings: Liping's compensation has increased whilst the company is unprofitable.
CEO
Liping Liu (54 yo)
6.8yrs
Tenure
CN¥14,663,000
Compensation
Dr. Liping Liu has been the Chief Executive Officer and Executive Director of HighTide Therapeutics, Inc. since February 28, 2018 and its chairwoman since December 22, 2023 She has been the Chief Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairwoman | 6.8yrs | CN¥14.66m | 0.96% HK$ 5.9m | |
| Deputy GM & Executive Director | 7.5yrs | CN¥10.83m | 0.34% HK$ 2.1m | |
| Chief Financial Officer | 2yrs | no data | no data | |
| Chief Development Officer | 3.8yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data | |
| Joint Company Secretary | no data | no data | no data |
2.9yrs
Average Tenure
54yo
Average Age
Experienced Management: 2511's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairwoman | 6.8yrs | CN¥14.66m | 0.96% HK$ 5.9m | |
| Deputy GM & Executive Director | 1.6yrs | CN¥10.83m | 0.34% HK$ 2.1m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | less than a year | CN¥4.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | 4.1yrs | CN¥1.84m | 0.17% HK$ 1.0m | |
| Independent Non-Executive Director | less than a year | CN¥4.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | 2.1yrs | no data | no data | |
| Non-Executive Director | 3.1yrs | CN¥8.90m | 0.19% HK$ 1.2m | |
| Independent Non-Executive Director | less than a year | CN¥4.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
1.8yrs
Average Tenure
54yo
Average Age
Experienced Board: 2511's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 18:50 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HighTide Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|